Jaguar Health (NASDAQ:JAGX) Shares Cross Below 200-Day Moving Average – Should You Sell?
by Mitch Edgeman · The Markets DailyJaguar Health, Inc. (NASDAQ:JAGX – Get Free Report)’s share price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $22.45 and traded as low as $4.29. Jaguar Health shares last traded at $4.37, with a volume of 29,507 shares.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on Jaguar Health in a research note on Friday, March 28th. They issued a “sell” rating for the company.
View Our Latest Stock Report on Jaguar Health
Jaguar Health Stock Down 4.0 %
The business’s fifty day simple moving average is $14.87 and its 200-day simple moving average is $22.40. The company has a current ratio of 1.84, a quick ratio of 1.36 and a debt-to-equity ratio of 1.65.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Jaguar Health stock. Virtu Financial LLC bought a new position in Jaguar Health, Inc. (NASDAQ:JAGX – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 25,591 shares of the biotechnology company’s stock, valued at approximately $35,000. Virtu Financial LLC owned about 0.22% of Jaguar Health at the end of the most recent quarter. Institutional investors and hedge funds own 12.04% of the company’s stock.
About Jaguar Health
Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
Featured Stories
- Five stocks we like better than Jaguar Health
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?
- Insider Trades May Not Tell You What You Think
- Disney 2025 Shareholders: Major Updates for Investors
- 3 Best Fintech Stocks for a Portfolio Boost
- Advance Auto Parts Stock: A Classic Rebound Play in the Making